In creating inter partes reexamination, Congress hoped to provide a faster, cheaper alternative for resolving questions of patent validity in the U.S. Patent & Trademark Office (USPTO) rather than in the courts. As a measure of the procedure’s growing popularity and availability, the rate of requests for inter partes reexamination has steadily increased each year, totaling over 308 since the procedure was created in November 1999. But, while the pace of reexam requests continues to increase, the end results of completed proceedings have received relatively little attention.
Read the complete article by clicking on the link below.
Author(s)
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.